Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Diageo

Disney

Digital Realty Trust

Ryanair Hlds

Toyota Motor

Looking for a bargain? Bottom-fishing investors may want to check out these stocks trading at a 52-week lows, or within 5% of that floor.

7 Stocks Trading at a 52-Week Low Worth Buying Now

Powered by a database of over 10,000 surgical cases, Medtronic continues to evolve the UNiD™ platform to help surgeons plan procedures, personalize care for their patients and predict post-operative spinal compensation   DUBLIN , July 14, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its UNiD™ Spine Analyzer v4.0 planning platform, which includes a new Degen Algorithm for degenerative spine procedures. The algorithm leverages machine learning to help surgeons plan and personalize procedures for patients undergoing lower lumbar spine surgery and predicts spinal compensation mechanisms six months after the operation.

Medtronic receives FDA clearance for next-generation UNiD™ Spine Analyzer with degenerative spine surgery predictive model

Chevron

Johnson & Johnson

TotalEnergies SE

Exxon Mobil

Amid an ailing stock market, shareholders wonder what the best mutual funds do that their own funds are not. And what are the best stocks to buy now?

Smart Buys, Sells That Make This American Century Fund Shine

Partnership underscores Medtronic's commitment to investing in innovative technologies that support physicians and patients from diagnosis to treatment  CathWorks' FFRangio® System provides diagnostic and physiologic information through artificial intelligence to potentially disrupt traditional FFR and revolutionize the management of coronary artery disease DUBLIN and KEFAR SAVA, Israel , July 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a strategic partnership agreement with CathWorks, a privately held company headquartered in Kefar Sava, Israel, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. As part of the agreement, Medtronic will invest up to $75 million and immediately begin co-promotion of CathWorks' FFRangio® System in the U.S., Europe and Japan, where it is commercially available.

Medtronic announces co-promotion agreement with CathWorks, with path toward acquisition

Occidental Petroleum

Following these legendary investors could help your portfolio weather any storm.

3 Stocks the World's Best Investors Are Buying Now

Amcor Plc

Caterpillar

Emerson Electric

General Dynamics

Genuine Parts

McDonald's

Procter & Gamble

Sherwin-Williams

Target

V.F.

I want to make certain that the Dividend Aristocrat I recommend will provide me with more than dividends. I want stock price appreciation as well.

S&P 500's Best Dividend Aristocrat Stocks To Consider

Novo Nordisk

These stocks are worth buying whether or not a recession is coming.

2 Safe Stocks That Can Survive Any Downturn

This leading medical device company just announced that it would be sending more cash to its shareholders each quarter.

Is This Beaten-Down Dividend Aristocrat a Buy?

Texas Instruments

Unilever

I don't buy stocks very often, but I recently jumped in to buy this trio paying their highest yields ever. Here's why.

3 Dividend Stocks With Elevated Yields I'd Buy Right Now Without Hesitation

Albemarle

Franklin Resources

Clorox

Ecolab

Lowe's

ProShares S&P 500 Dividend Aristocrats ETF

Nucor

Stanley Black & Decker

Sysco

T. Rowe Price Group

Walgreens

NOBL gains 0.31% in May but is down 5.99% in 2022 after the first 5 months. Thus far, through June 28th, the dividend aristocrat ETF is down 6.22%, inclusive of its dividend payment this month.

My Best Dividend Aristocrats For July 2022

GOTHENBURG, Sweden , June 29, 2022 /PRNewswire/ -- Mentice, Gothenburg (STO: MNTC), a world leader in simulation solutions for image-guided interventional therapies, announced today that Medtronic, Dublin (NYSE: MDT), a global healthcare technology leader, has signed an agreement to acquire Mentice VIST® simulation solutions and development services, in an initial order of USD 1.93 million. The initial order includes the development services and 10 simulation solutions for delivery in 2022 raising to an additional intention of 150 simulation solutions over 3 years.

Mentice receives an initial order of USD 1.93million for simulation solutions and development services from Medtronic

NIKE

Taiwan Semiconductor Manufacturing

Weyerhaeuser

As we approach the halfway point of 2022, several of Jeff Auxier (Trades, Portfolio)'s stocks are trading close to their 52-week lows.

6 Jeff Auxier Stocks Approaching 52-Week Lows

DUBLIN , June 27, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced that its Board of Directors appointed Lidia Fonseca, Executive Vice President, Chief Digital and Technology Officer at Pfizer, to the Board as an independent director, effective June 27, 2022. Ms. Fonseca will serve on the Compensation Committee and Science and Technology Committee of the Board.

Medtronic Board appoints Lidia Fonseca as a new director

Digital Health Innovator Cloud DX Grows US and Canada Business, Increases Workforce, and Secures Patents with Support from the FedDev Business Scale Up Program News in Summary Successful completion of 2-year program with $500,00 in non-dilutive funding. 2 new US patents and 4 published peer-reviewed papers.

Cloud DX Completes Federal Project to Scale Up, Create Jobs, and Expand Intellectual Property (IP)

Movin' on up. That's the expectation for Medtronic PLC ( MDT , Financial), which is forecasted to boost its share of a worldwide medtech market that is pegged to grow 5% a year, reaching three-quarters of a trillion dollars by 2028.

Medtronic Forecasted to Retain Top Medtech Market Share

Booking Hlds

These are the stocks that the world's most successful money managers bought while stock markets tanked.

3 Stocks the World's Best Investors Are Buying in a Bear Market

Enbridge

Essex Property Trust

Fresenius Medical Care

Altria

Novartis

Roche Holding AG

This bear market is the 2nd worst start to the year in US stock market history. And cracks are beginning to form in credit markets that could potentially send stocks falling even lower in the coming months.

My, Oh, My 11 Incredible High-Yield Dividend Aristocrat Bear Market Buys

Community Trust Bancorp

Leggett & Platt

Old Republic International

Sonoco Products

Telephone and Data Systems

United Bankshares

Universal Corp

Drip Investing lists over 800 stocks that have annually increased dividends for 5 years or more. As of June, 62 stocks have hiked their dividends annually 40 years or more. Parsed from 129 Champions, utilizing YCharts-data as of 6/16/22, those 62 select-dividend stocks ranged 0.93% to 5.66% in annual yield, and ranged -0.97% to 55.33% in analyst 1-yr price-target upsides.

40Yr+Dividend Growers Sprout 8 Buys In June

Alnylam Pharmaceuticals

Baxter

Biogen

Boston Scientific

If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.

Seven reasons the beleaguered biotech sector is now a ‘buy'

News for Medtronic Stock (MDT)